WO2005097086A2 - Use of 5,10-methylene tetrahydrofolate for the treatment of cancer - Google Patents

Use of 5,10-methylene tetrahydrofolate for the treatment of cancer Download PDF

Info

Publication number
WO2005097086A2
WO2005097086A2 PCT/US2005/011046 US2005011046W WO2005097086A2 WO 2005097086 A2 WO2005097086 A2 WO 2005097086A2 US 2005011046 W US2005011046 W US 2005011046W WO 2005097086 A2 WO2005097086 A2 WO 2005097086A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
anticancer drug
additional anticancer
dosage
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/011046
Other languages
English (en)
French (fr)
Other versions
WO2005097086A3 (en
Inventor
Joan M. Robbins
Mark J. Cantwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savara Inc
Original Assignee
Adventrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adventrx Pharmaceuticals Inc filed Critical Adventrx Pharmaceuticals Inc
Priority to AU2005231436A priority Critical patent/AU2005231436A1/en
Priority to CA002561952A priority patent/CA2561952A1/en
Priority to EP05732160A priority patent/EP1740182A2/en
Priority to US10/594,850 priority patent/US20070280944A1/en
Priority to JP2007506303A priority patent/JP2007531728A/ja
Publication of WO2005097086A2 publication Critical patent/WO2005097086A2/en
Publication of WO2005097086A3 publication Critical patent/WO2005097086A3/en
Priority to IL178261A priority patent/IL178261A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Cancer is a major public health concern. Colorectal cancer alone causes approximately 50,000 deaths per year in the United States. Nearly half of the approximately 130,000 cases of colorectal cancer that are diagnosed every year present with or develop into metastatic disease, for which chemotherapy is the only treatment. New effective drug-based therapies for treatment are urgently sought not only for colorectal cancers, but for other cancers such as, for example, breast cancer, pancreatic cancer, stomach cancers, hepatic cancer, bladder cancer, cervical cancer, head and neck cancers, lung cancers, ovarian cancer, and prostate cancer.
  • the anticancer drug 5-fluorouracil (5-FU) is converted in the body to FdUMP, an inhibitor of thymidylate synthase (TS), an enzyme required for nucleic acid biosynthesis.
  • 5-FU is commonly used to treat cancers such as colorectal and breast cancer, as well as head and neck cancer, pancreatic cancer, stomach cancer, and non-small-cell lung cancer.
  • 5-FU is commonly used in conjunction with folinic acid (FA, leucovorin), which is converted intracellularly into reduced fo ⁇ ns of folate (5,10-methylene tetrahydrofolate or polyglutamates of 5,10-methylene tetrahydrofolate), that are cofactors for thymidylate synthase.
  • F folinic acid
  • leucovorin folinic acid
  • the combination of 5-FU and leucovorin has been found to have increased anti- tumor effects when compared with the use of 5-FU alone.
  • 5-FU and 5-FU in combination with leucovorin have been used in combination with other anticancer agents to improve survivorship of patients having recurrent colorectal, breast, stomach, or other cancers.
  • 5,10-methylene tetrahydrofolate (“5,10-CH 2 -THFA”) is a reduced folate that can act as a cofactor for thymidylate synthase, either directly or after conversion to its polyglutamates.
  • Toxicities associated with 5-FU include stomatitis, mucositis, gastrointestinal symptoms, and hematological toxicity, particularly neutropenia, thrombocytopenia, and leucopenia.
  • Toxicity can limit the treatment available to the patient, either by limiting the dosages of anti-cancer agents or by limiting the armory available to the clinician in treating the cancer patient.
  • Toxicity can limit the treatment available to the patient, either by limiting the dosages of anti-cancer agents or by limiting the armory available to the clinician in treating the cancer patient.
  • the present invention provides novel uses for 5,10-methylene tetrahydrofolate ("5,10-CH 2 -THFA") in the treatment of cancer which provide reduced toxicity to the patient and greater efficacy than current modalities.
  • the present invention is based on the su ⁇ rising result that 5,10-CH 2 -THFA, while increasing the efficacy of 5- FU in reducing the rate of tumor growth and increasing survivorship, also reduces the toxicity to the patient of 5-FU.
  • treatment with 5,10-CH 2 -THFA and 5-FU reduces tumor growth rate and increases survivorship of tumor-bearing animals with respect to treatment with either 5- FU alone, or 5-FU in combination with leucovorin (folinic acid; FA), while demonstrating less toxicity than either treatment.
  • the present invention is further based on the finding that treatment of tumor- bearing animals with 5,10-CH 2 -THFA and 5-FU and additional anticancer drugs can also improve outcomes with respect to single modality treatments or alternative combination treatments that include the use of 5-FU with leucovorin.
  • the invention provides methods of treating cancer patients with combination chemotherapy that includes 5-fluorouracil (5-FU) or an analog or prodrug of 5-FU; 5,10- CH 2 -THFA; and one or more additional anti-cancer drugs.
  • the one or more additional anticancer drugs can be one or more chemotherapeutic agents of any type, including but not limited to chemotherapeutic agents that comprise specific binding members, proteins, nucleic acids, lipids, steroids, large molecules, small molecules, or metals.
  • the one or more anticancer drugs can comprise one or more of: alkylating agents, antimetabolites, mitotic inhibitors, topoisomerase inhibitors, microtubule disrupting drugs, nucleic acid synthesis inhibitors, kinase inhibitors, hormone blocking drugs, proteosome inhibitors, vascularization inhibitors, immune modulators, anti-inflammatory drugs, cytokines, inhibitors of cytokines, receptor-binding drugs, or 5- FU modulators.
  • the method includes: administering 5- FU or an analog or prodrug thereof, 5,10- CH 2 - THFA, and at least one additional anticancer drug to a patient with cancer.
  • compositions for the treatment of cancer that comprise: 5- FU or an analog or prodrug thereof, 5,10- CH 2 -THFA, and at least one additional anticancer drug.
  • the one or more additional anticancer drugs can be one or more chemotherapeutic agents of any type, including but not limited to chemotherapeutic agents that comprise specific binding members, proteins, nucleic acids, lipids, steroids, large molecules, small molecules, or metals.
  • the one or more anticancer drugs can comprise one or more of: alkylating agents, antimetabolites, mitotic inhibitors, topoisomerase inhibitors, microtubule disrupting drugs, nucleic acid biosynthesis inhibitors, kinase inhibitors, hormone blocking drugs, proteosome inhibitors, vascularization inhibitors, immune modulators, anti-inflammatory drugs, cytokines, inhibitors of cytokines, receptor-binding drugs, or 5- FU modulators.
  • a multidrug composition of the present invention can be provided in one or more than one formulation.
  • a third aspect of the present is the use of 5,10-CH 2 -THFA in combination with 5- FU or an analog or prodrug thereof and at least one additional chemotherapeutic agent in the manufacture of a composition for the treatment of cancer where the at least one additional chemotherapeutic agent is selected from the group consisting of: alkylating agents, antimetabolites, topoisomerase inhibitors, microtubule disrupting drugs, nucleic acid biosynthesis inhibitors, kinase inhibitors, hormone blocking drugs, proteosome inhibitors, vascularization inhibitors, immune modulators, anti-inflammatory drugs, cytokines, inhibitors of cytokines, receptor-binding drugs, or 5- FU modulators.
  • the use includes manufacturing the pharmaceutical composition as a single formulation or as more than one formulation.
  • the present invention provides methods for decreasing the toxicity to a patient of a cancer drug treatment regimen that includes administration of 5-
  • the present invention includes methods for decreasing toxicity of an analog or prodrug of 5- FU, such as, but not limited to capecitabine, by co-administering 5,10-CH 2 -THFA.
  • the present invention includes methods for decreasing the toxicity of an anticancer treatment that comprises administering 5-FU or an analog or prodrug of 5-FU and an additional anticancer drug
  • a fifth aspect of the present invention is a method of reducing the toxicity to a patient of a anticancer drug treatment regimen that includes 5- FU or an analog or prodrug of 5-FU and leucovorin, comprising substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the anticancer drug regimen.
  • the present invention includes methods for decreasing toxicity of an anticancer drug regimen that includes an analog or prodrug of 5-FU, such as, but not limited to, capecitabine, and leucovorin where toxicity of the regimen is decreased by substituting 5,10-CH 2 -THFA for leucovorin in the regimen.
  • an analog or prodrug of 5-FU such as, but not limited to, capecitabine
  • leucovorin where toxicity of the regimen is decreased by substituting 5,10-CH 2 -THFA for leucovorin in the regimen.
  • the present invention includes methods for decreasing the toxicity of an anticancer treatment that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the drug regimen.
  • the present invention provides methods for increasing the efficacy of a cancer drug treatment regimen that includes administration of 5- FU or an analog or prodrug of 5-FU to a cancer patient by co-administering 5,10- 5,10-CH 2 - THFA.
  • the present invention includes methods for increasing the efficacy of an analog or prodrug of 5-FU, such as, but not limited to capecitabine, by co-administering 5,10-CH 2 -THFA.
  • the present invention includes methods for increasing the efficacy of an anticancer treatment that comprises administering 5-FU or an analog or prodrug of 5-FU and an additional anticancer drug
  • a seventh aspect of the present invention is a method of increasing the efficacy to a patient of a anticancer drug treatment regimen that includes 5- FU or an analog or prodrug of 5-FU and leucovorin, comprising substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the anticancer drug regimen.
  • the present invention includes methods for increasing efficacy of an anticancer drug regimen that includes an analog or prodrug of 5-FU, such as, but not limited to, capecitabine, and leucovorin where efficacy of the regimen is increased by substituting 5,10-CH 2 -THFA for leucovorin in the regimen.
  • an analog or prodrug of 5-FU such as, but not limited to, capecitabine
  • leucovorin where efficacy of the regimen is increased by substituting 5,10-CH 2 -THFA for leucovorin in the regimen.
  • the present invention includes methods for increasing the efficacy of an anticancer treatment that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by substituting 5,10-CH 2 -THFA for leucovorin in the drug regimen.
  • the invention provides a method of increasing the dose of 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by substituting 5,10-CH 2 -THFA for leucovorin in the drug regimen.
  • the invention provides a method of increasing the dose of 5-
  • the method includes: obtaining an anticancer drug regimen that includes 5- FU or an analog or prodrug of 5-FU and leucovorin; substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the anticancer drug regimen; and increasing the dosage of 5-FU or an analog or prodrug of 5-FU in the anticancer drug regimen.
  • substituting 5,10-CH 2 -THFA for leucovorin in the anticancer while increasing the dosage of 5-FU can increase the efficacy of a treatment without prohibitively increasing toxicity.
  • the invention provides a method of increasing the dose of an additional anticancer drug in an anticancer drug regimen that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and an additional anticancer drug.
  • the method includes: obtaining an anticancer drug regimen that includes 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5- FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase); substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug regimen; and increasing the dosage of the one or more additional anticancer drugs in the anticancer drug regimen.
  • substituting 5,10-CH 2 -THFA for leucovorin in the anticancer while increasing the dosage an additional anticancer drug used in the regimen can increase the efficacy of a treatment without prohibitively increasing toxicity.
  • Figure 1 is a graph depicting growth kinetics of HT-29 tumor in Nude mice treated with combinations of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; anti-VEGF (Avastin); and leucovorin.
  • HT-29 tumor volumes were plotted against time from treatment initiation with the indicated drugs. Mean tumor volume + standard error of the mean are plotted. Curves were generated by best-fit analysis.
  • Figure 2 is a graph depicting growth kinetics of HT-29 tumor in Nude mice treated with combinations of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; and oxaliplatin.
  • HT-29 tumor volumes were plotted against time from treatment initiation with the indicated drugs. Mean tumor volume + standard error of the mean are plotted. Curves were generated by best-fit analysis.
  • Figure 3 is a graph depicting mean tumor volumes following treatment of Nude mice bearing HT-29 tumor with combinations of 5-FU; 5,10-CH -THFA, here represented as "CoFactor”; anti-VEGF (Avastin); and leucovorin. Mean tumor volumes 22 days following treatment initiation were plotted for each treatment group. Error bars represent standard error of the means.
  • Figure 4 is a graph depicting mean tumor volumes following treatment of Nude mice bearing HT-29 tumor with combinations of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; and oxaliplatin. Mean tumor volumes 22 days following treatment initiation were plotted for each treatment group. Error bars represent standard error of the means.
  • Figure 5 depicts Kaplan-Meier plots of survival of Nude mice bearing HT-29 tumor following treatment with combinations of 5-FU; 5,10-CH -THFA, here represented as “CoFactor”; leucovorin; and anti-VEGF (Avastin).
  • Figure 6 depicts Kaplan-Meier plots of survival of Nude mice bearing HT-29 tumor following treatment with combinations of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; and oxaliplatin.
  • Figure 7 is a graph depicting HT-29 tumor growth kinetics in Nude mice treated with combinations 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; leucovorin; and anti-VEGF (Avastin).
  • HT-29 tumor volumes were plotted against time from treatment initiation. Mean tumor volume + standard error of the mean are plotted. Curves were generated by best-fit analysis.
  • Figure 8 is a graph depicting mean tumor volumes following treatment of Nude mice bearing HT-29 tumor with combinations of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; leucovorin; and anti-VEGF (Avastin). Mean tumor volumes 19 days following treatment initiation were plotted for each treatment group. Error bars represent standard error of the means .
  • Figure 9 is a Kaplan-Meier plot of survival of Nude mice bearing HT-29 tumor following treatment with combination of 5-FU; 5,10-CH 2 -THFA, here represented as "CoFactor”; and anti-VEGF (Avastin).
  • Figure 10 is a Kaplan-Meier plot of survival of Balb/c mice following treatment with 5- FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • Figure 11 is a graph depicting blood analysis of Balb/c mice following treatment with 5- FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor"). Blood measurements taken 1 week after drug therapy were divided by the pre-treatment blood measurements to calculate the percentage baseline measurement plotted in the graph. Mean data values + standard errors of the means are plotted for each treatment group.
  • WBC white blood cells
  • RBC red blood cells
  • HGB hemoglobin
  • HCT hemoglobin
  • MCV mean cell volume
  • MCH mean cell hemoglobin
  • MCHC mean cell hemoglobin content
  • PLT platelets.
  • Figure 12 is a graph depicting platelet toxicity grading of Balb/c mice following treatnent with 5-FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • One week following drug treatment the grade of platelet toxicity was calculated for each mouse. The percentages of mice with grade 1 or 2, grade 3, and grade 4 toxicity are plotted for each treatment group.
  • Figure 13 is a graph depicting neutrophil toxicity grading of Balb/c mice following treatment with 5-FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • 5-FU 5-FU/leucovorin
  • 5-FU/5,10-CH 2 -THFA 5-FU/5,10-CH 2 -THFA
  • One week following drug treatment the grade of neutrophil toxicity was calculated for each mouse. The percentages of mice with grade 1 or 2, grade 3, and grade 4 toxicity in each treatment group are plotted.
  • Figure 14 is a graph depicting neutrophil toxicity analysis of Balb/c mice following treatment with 5-FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • 5-FU 5-FU
  • 5-FU/leucovorin 5-FU/5,10-CH 2 -THFA
  • Five,10-CH 2 -THFA is labeled as "CoFactor”
  • mice with grade 4 neutrophil toxicity were subdivided based on their absolute neutrophil counts. The percentages of these mice with the indicated neutrophil cell counts are plotted for each treatment group.
  • Figure 15 is a graph depicting weight loss toxicity grading of Balb/c mice following treatment with combinations of 5-FU; leucovorin; 10-CH 2 -THFA, here labeled as "CoFactor”; and gemcitabine.
  • One week following drug treatment the grade of weight loss toxicity was calculated for each mouse. The percentages of mice with grade 0, 1, 2, and 3 toxicity are plotted for each treatment group.
  • Gem Gemcitabine
  • Figure 16 is a graph depicting percent weight loss of Balb/c mice following treatment with combinations of 5-FU; leucovorin; 10-CH 2 -THFA, here labeled as "CoFactor”; and gemcitabine.
  • One week following drug treatment the percentage weight loss from the starting baseline weights were calculated for each mouse. The percentages of mice that fell with the ranges of weight loss indicated in the legend were then plotted for each treatment group.
  • Gem Gemcitabine
  • Figure 17 is a Kaplan-Meier survival plot of Balb/c mice following treatment with combinations of 5-FU; leucovorin; 10-CH 2 -THFA, here labeled as "CoFactor”; and gemcitabine.
  • Gem Gemcitabine
  • Figure 18 is a graph depicting lymphopenia toxicity grading of Balb/c mice following treatment with 5-FU, 5-FU/leucovorin, and 5-FU/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • One week following drug treatment the grade of lymphopenia was calculated for each mouse. The percentages of mice with grade 1/2, grade 3, and grade 4 toxicity are plotted for each treatment group.
  • Figure 19 is a graph depicting HT-29 tumor growth kinetics in Nude mice treated with capecitabine (Xeloda), Xeloda/leucovorin, and Xeloda/5,10-CH 2 -THFA (5,10-CH 2 - THFA is labeled as "CoFactor").
  • HT-29 tumor volumes were plotted against time from treatment initiation. Mean tumor volume + standard error of the mean are plotted. Curves were generated by best-fit analysis.
  • Figure 20 is a Kaplan-Meier survival plot of Balb/c mice following treatment with capecitabine (Xeloda), Xeloda/leucovorin, and Xeloda/5,10-CH 2 -THFA (5,10-CH 2 - THFA is labeled as "CoFactor").
  • Figure 21 is a graph depicting weight loss toxicity of Balb/c mice following eight days of treatment with capecitabine (Xeloda), Xeloda/leucovorin, and Xeloda/5,10-CH 2 -THFA (5,10-CH 2 -THFA is labeled as "CoFactor").
  • capecitabine Xeloda
  • Xeloda/leucovorin Xeloda/5,10-CH 2 -THFA
  • Xeloda/5,10-CH 2 -THFA 5,10-CH 2 -THFA is labeled as "CoFactor”
  • An “anticancer drug” is any drug used in the treatment of cancer.
  • Some nonlimiting examples of some investigational anticancer drugs that can be used in the methods and compositions of the present invention are provided in Table 1.
  • a "chemotherapeutic agent” is any chemical entity having biological activity and useful in the treatment of disease.
  • a chemotherapeutic agent is a chemical entity that directly or indirectly causes the death of cancer cells.
  • a chemotherapeutic agent can have anti-cancer effects either as a single agent or in combination with one or more other chemotherapeutic agents.
  • An "analog" of an anticancer drug or chemotherapeutic agent is a chemical compound that is structurally similar to the anticancer drug or chemotherapeutic agent but differs slightly in composition (as in the replacement of one atom by an atom of a different element or the addition or substitution of a particular functional group).
  • an analog can also mean a chemical compound the is structurally similar or identical but also includes additional moieties that can, for example, enhance solubility, retard degradation, increase half-life in the circulation, confer membrane permeability, or direct tissue or cellular targeting, for example.
  • an analog of a compound, anticancer drug or chemotherapeutic agent has essentially the same activity as the compound, anticancer drug or chemotherapeutic agent when administered to the patient in a therapeutically effective amount.
  • a "prodrug” of an anticancer drug or chemotherapeutic agent is a molecule which is converted within the body to the anticancer drug or therapeutic agent but on its own either has no activity or has an activity quantitatively or qualitatively different from that of the anticancer drug.
  • an "anticancer drug regimen”, a “chemotherapy drug regimen”, an “anticancer drug protocol,” or a “chemotherapy protocol” is a formal outline or plan of what treatments a cancer patient will receive and exactly when and in what dosages each should be given.
  • TS is a reduced folate molecule such as 5,10-CH 2 -THFA or a polyglutamate of 5,10- CH 2 -THFA that can enhance the inhibition of thymidylate synthase by 5-FU.
  • a "folate cofactor of thymidylate synthase” can also be a precursor or prodrug of a folate molecule that enhances the inhibition of thymidylate synthase.
  • a folate cofactor such as folinic acid (5-formyl-tetrahydrofolate, leucovorin) can be converted to 5 , 10-CH 2 -THF A and polyglutamates of 5 , 10-CH 2 -THFA in the body.
  • Toxicity refers to harmful effects of an entity on the cells, tissues, organs, or systems of the body. Toxic effects result from biochemical reactions of the entity with the cells or tissues of the subject being treated, and can be general or specific, involving a particular system or organ.
  • Toxicity can include, as nonlimiting examples, increased lacrimation; mucositis; esophagopharyngitis; neurological toxicity, such as parasthesias, insomnia, and dizziness; gastrointestinal toxicity, such as nausea, vomiting, and diarrhea; weight loss toxicity; cardiac toxicity; dermatological toxicity, including alopecia, sweating, and rashes; and hematological toxicity, such as, but not limited to, neutropenia, thrombocytopenia, lymphopenia, and leucopenia.
  • Clinical definitions of toxicity parameters can be found in the National Cancer Institute's Common Toxicity Criteria (version 3) or in the World Health Organization Toxicity Criteria.
  • Effectiveness of an anticancer treatment or chemotherapy regimen is determined by its anti-tumor or anti-cancer cell effects and ability to improve clinical results of treatment, such as, for example, remission, time to progression, response rate, and survivorship.
  • Accepted methods of assessing the efficacy of an anticancer treatment or chemotherapy regimen are well-established in the field of cancer treatment.
  • anti-cancer effects can be assessed by detecting cancer cells or markers, for example in serum or plasma. Examples of tumor proteins or antigens that can be detected include CEA for colon cancer and CA 19-9 for pancreatic cancer.
  • anti-tumor effects can be measured by monitoring tumor size and the change in tumor size over time.
  • Nonsteroidal Anti-Inflammatory '"Miscellaneous I Methods of Treating a Patient with Cancer Using a Combination Therapy that Includes 5-FU, 5,10- CH?-THFA, and at least one additional Anticancer Drug
  • the invention provides methods of treating cancer patients with combination chemotherapy that includes: 5- 5-FU or an analog or prodrug of 5-FU; 5,10-CH -THFA; and one or more additional anti-cancer drugs.
  • the one or more additional anticancer drugs can be one or more chemotherapeutic agents of any type, including but not limited to chemotherapeutic agents that comprise specific binding members, proteins, nucleic acids or nucleic acid analogs (such as, but not limited to antisense molecules, ribozymes, and siRNAs), lipids, steroids, large molecules, small molecules, or metals.
  • chemotherapeutic agents that comprise specific binding members, proteins, nucleic acids or nucleic acid analogs (such as, but not limited to antisense molecules, ribozymes, and siRNAs), lipids, steroids, large molecules, small molecules, or metals.
  • the one or more anticancer drugs can comprise one or more chemotherapeutic agents, such as but not limited to: topoisomerase inhibitors (e.g., irinotecan, topotecan), antimetabolite drugs (e.g., methotrexate, gemcitabine, tezacitabine ), 5-FU modulators, alkylating agents (e.g., cyclophosphamide, carmustine), nucleic acid biosynthesis inhibitors (e.g., mitomycin, doxorubicin, cisplatin, oxaliplatin), microtubule disrupting drugs (e.g., paclitaxel, docetaxel, vinolrebine, vincristine), hormone blocking drugs (e.g., tamoxifen), inhibitors of kinases, including but not limited to receptor and nonreceptor tyrosine kinases (e.g., Iressa, Tarceva, SU5416, PTK787, Glee
  • Anticancer drugs can also be a drug under investigation for potential anti-cancer activity, such as those listed in Table 1.
  • Anticancer drugs include monoclonal antibodies, such as but not limited to monoclonal antibodies that bind cytokines, hormones, or hormone receptors (e.g., antibodies that block activation of EGF or VEGF growth factors, such as Avastin, erbutux, herceptin), etc.
  • the method includes: administering 5-FU or an analog or prodrug thereof; 5,10- CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • an "additional" anti-cancer drug is an anti-cancer drug that is not 5,10-CH 2 - THF A, 5-FU or an analog or prodrug of 5-FU, or leucovorin.
  • a cancer patient can be a patient with any type of cancer.
  • the patient has a tumor type that in current practice is commonly treated with 5-FU, such as, for example, colorectal carcinoma, pancreatic, breast, head and neck, esophageal cancer, or stomach cancer.
  • the patient has a tumor type that in current practice is not commonly treated with 5-FU, such as, but not limited to ovarian cancer or cervical cancer.
  • combination therapies that use 5,10-CH 2 - THFA, 5-FU (or an analog or prodrug thereof), and one or more additional anti-cancer drugs have potential for treating cancers other than those currently commonly treated with 5-FU.
  • Those skilled in the art of cancer treatment and chemotherapy would be able to determine optimal dosages and regimens for 5,10-CH -THFA and 5-FU using well- established protocols for evaluating toxicity and efficacy.
  • Some preferred treatments of cancer patients with 5-FU and 5,10-CH 2 -THFA are regimens using from 10 milligrams to 1 gram of 5,10- CH 2 -THFA per m 2 , preferably from 20 milligrams to 500 milligrams of 5,10- CH 2 -THFA per m 2 , and more preferably from about 30 milligrams to about 250 milligrams of 5,10-CH -THFA per m 2 .
  • a preferred dose of 5,10-CH 2 -THFA can be from about 30 to about 120 milligrams per m .
  • Dosage of 5- FU can be from about 25 milligrams to about 5 grams per m 2 , and is preferably from about 50 milligrams to 2.5 grams per ffi 2 , and more preferably from about 100 milligrams to about 1 gram per m 2 .
  • a preferred dose of 5- FU can be from about 250 to about 700 milligrams per m 2 .
  • 5-FU can be administered by any feasible means, including injection or IV feed.
  • a prodrug or analog of 5-FU is used in combination therapy rather than 5-FU itself.
  • 5-FU is converted to 5-fluoro-2'-deoxyuridylate (FdUMP) the inhibitor of thymidylate synthase.
  • FdUMP 5-fluoro-2'-deoxyuridylate
  • analog or prodrug of 5-FU is used to mean an analog or prodrug that can be directly or indirectly converted to an inhibitor of thymidylate synthase, such as FdUMP.
  • One prodrug of 5-FU that can be used in the methods of the present invention is N4-pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
  • the method of the present invention comprises administering N4- pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine); 5,10-CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of capecitabine can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the of daily dosage of capecitabine can be from about 500 mg to about 7500 9 mg per m , preferably from about 1000 mg to about 5000 mgs per m , and more preferably from about 1500 mg to about 3000 mg per m 2 .
  • the dose can be divided into one to six (preferably two) administrations per day.
  • the foregoing are general guidelines only that can be expanded or altered based on for example, cancer type and grade, patient age, health status, and sex, the particular drugs used in combination, the route and frequency of administration, and experimental and clinical findings using a multidrug combination.
  • Capecitabine can be administered by any feasible means including injection, IV feed, or in an oral formulation.
  • an analog combination that can be used in the methods of the present invention is Tegafur (TF) and uracil (U) used in a 1:4 combination known as UFT.
  • the method of the present invention comprises administering UFT; 5,10- CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of UFT can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the daily dosage of UFT can be from about 50 mg to about 3000 mg per m 2 , preferably from about 100 mg to about 2000 mg per m 2 , and more preferably from about 200 mg to about 1000 mg per m 2 .
  • Anticancer regimens that include UFT can optionally also include calcium folinate administered with UFT.
  • UFT can be administered by any feasible means, including injection, IV feed, or in an oral formulation.
  • Dosage for the one or more additional anticancer drugs used in a multidrug regimen of the present invention can also be determined by studies using escalating dosages and monitoring of toxicity and efficacy. In determining dosages of an anticancer drug to be used in combination therapy that have been used independently in chemotherapy regimens, practitioners can take into account dosages of drugs used in established chemotherapy regimens.
  • the reduced toxicity of 5-FU (or an analog or prodrug thereof) when combined with 5,10-CH 2 -THFA can permit drug regimens in which 5,10-CH 2 -THFA and 5-FU (or an analog or prodrug thereof) are used in combination with one or more additional anticancer drugs that would be prohibitively toxic in the absence of CH 2 -THFA.
  • the drugs can be administered intravenously, orally, or by any other feasible means, according to regimens that can be determined by qualified clinicians.
  • the anticancer drugs used in the combination protocols of the present invention can be administered separately or one or more of the anticancer drugs used in the combination protocols can be administered together. Where one or more anticancer drug is administered separately, the timing and schedule of administration of each drug can vary.
  • bolus injection of each drug can be given once weekly for a number of weeks.
  • 5,10- CH -THFA is administered prior to 5- FU or 5-FU analog or prodrug.
  • the patient can receive the 5,10- CH 2 -THFA dose from about 10 minutes to about four hours prior to receiving the 5- FU dose.
  • An additional anticancer drug used in combination therapy can be administered before, during, or after administration of 5- FU (or an analog or prodrug thereof), or can be administered during periods in which the patient does not receive 5-FU (or an analog or prodrug thereof) and 5,10- CH 2 -THFA.
  • the protocol for the combination therapy is not limiting, and can include many any feasible administration protocols with respect to frequency, duration, and dosage.
  • treating a cancer patient with 5,10-CH -THFA, 5-FU (or an analog or prodrug thereof), and one or more additional anti-cancer drugs can reduce the rate of tumor growth in a cancer patient when compared with treating the patient with the one or more additional anti-cancer drugs in the absence of 5,10-CH 2 -THFA and 5-FU (or an analog or prodrug thereof), or when compared with treating a patient with 5-FU (or an analog or prodrug thereof) and the one or more additional anti-cancer drugs in the absence of 5, 10-CH 2 -THFA.
  • treating cancer patients with 5,10-CH 2 -THFA, 5-FU (or an analog or prodrug thereof), and one or more additional anti-cancer drugs can increase the survivorship of cancer patients when compared with treating cancer patients with the one or more additional anti-cancer drugs in the absence of 5,10-CH 2 -THFA and 5-FU (or an analog or prodrug thereof) or when compared with treating cancer patients with 5-FU (or an analog or prodrug thereof) and the one or more additional anti-cancer drugs in the absence of 5,10-CH 2 -THFA.
  • compositions for the Treatment of Cancer comprising 5-FU, 5,10-Methylene Tetrahydrofolate, and at least one additional Anticancer Drug
  • a second aspect of the present invention is compositions for the treatment of cancer that comprise: 5-FU or an analog or prodrug thereof, 5,10-CH 2 -THFA, and at least one additional anticancer drug.
  • the one or more additional anticancer drugs can be one or more chemotherapeutic agents of any type, including but not limited to chemotherapeutic agents that comprise specific binding members, proteins, nucleic acids or nucleic acid analogs (such as, but not limited to antisense molecules, ribozymes, and siRNAs), lipids, steroids, large molecules, small molecules, or metals.
  • the one or more anticancer drugs can comprise one chemotherapeutic agents, such as but not limited to: topoisomerase inhibitors (e.g., irinotecan, topotecan), antimetabolite drugs (e.g., methotrexate, gemcitabine), mitotic inhibitors, 5-fluorouracil modulators, alkylating agents (e.g., cyclophosphamide, carmustine), nucleic acid biosynthesis inhibitors (e.g., mitomycin, doxorubicin, cisplatin, oxaliplatin), microtubule disrupting drugs (e.g., paclitaxel, docetaxel, vinolrebine, vincristine), hormone blocking drugs (e.g., tamoxifen), inhibitors of kinases, including but not limited to receptor and nonreceptor tyrosine kinases (e.g., Iressa, Tarceva, SU5416, PTK787, Gleeve
  • An anticancer drug can also be a drug under investigation for potential anti-cancer activity, such as those listed in Table 1.
  • Anti- cancer drugs include monoclonal antibodies, such as but not limited to monoclonal antibodies that bind cytokines, hormones, or hormone receptors (e.g., antibodies that block activation of EGF or VEGF growth factors, such as Avastin, erbutux, herceptin), etc.
  • the present invention includes anticancer drug combinations that include 5-FU (or an analog or prodrug thereof), 5,10-CH -THFA, and one or more additional anticancer drugs formulated as pharmaceutical compositions.
  • An anticancer drug combination can comprise one or more pharmaceutical formulations.
  • 5-FU or an analog or prodrug thereof
  • 5,10-CH 2 -THFA and one or more additional anticancer drugs
  • two or more of 5-FU (or an analog or prodrug thereof), 5, 10-CH 2 -THFA, and one or more additional anticancer drugs can be provided together in a formulation.
  • Separate formulations that are used in a multidrug anticancer regimen of the present invention can be designed for the same or different routes of administration.
  • the present invention also includes the use of 5-FU or an analog or prodrug thereof, 5,10-CH 2 -THFA, and at least one additional anticancer drugs in the manufacture of a pharmaceutical composition for the treatment of cancer.
  • the at least one additional anticancer drug can be any of the following: a topoisomerase inhibitor (e.g., irinotecan, topotecan), an antimetabolite drug (e.g., methotrexate, gemcitabine), a mitotic inhibitor, a 5-Fu modulator, an alkylating agent (e.g., cyclophosphamide, carmustine), a nucleic acid biosynthesis inhibitor (e.g., mitomycin, doxorubicin, cisplatin, oxaliplatin), a microtubule disrupting drug (e.g., paclitaxel, docetaxel, vinolrebine, vincristine), a hormone blocking drug (e.g., tamoxifen), an inhibitor of kinases, including but not limited to receptor and nonreceptor tyrosine kinases (e.g., Iressa, Tarceva, SU5416, PTK787, Gleevec
  • the use includes manufacturing the pharmaceutical composition as a single formulation or as more than one formulation.
  • 5-FU may be provided as an injectable aliquot and 5,10- CH 2 -THFA and at least one additional anticancer drug may be provided as an additional injectable aliquot to be administered prior to the 5-FU dose.
  • 5-FU, 5,10- CH 2 -THFA, and at least one additional anticancer drug can all be provided in separate formulations, so that each can be administered separately, and where each drug aliquot is manufactured to have the appropriate dose for a particular combination drug regimen.
  • the pharmaceutical compositions comprise a pharmaceutically acceptable carrier prepared for storage and preferably subsequent administration, which have a pharmaceutically effective amount of the compound in a pharmaceutically acceptable carrier or diluent.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990)).
  • Preservatives, stabilizers, dyes and even flavoring agents can be provided in the pharmaceutical composition.
  • sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid can be added as preservatives.
  • antioxidants and suspending agents can be used.
  • compositions of the present invention can be formulated and used as tablets, capsules or solutions for oral administration; salves or ointments for topical application; suppositories for rectal administration; sterile solutions, suspensions, and the like for use as inhalants or nasal sprays.
  • injectables can also be prepared in conventional forms either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride and the like.
  • the injectable pharmaceutical compositions can contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents and the like.
  • the pharmaceutically effective amount of a composition required as a dose will depend on the route of administration, the type of cancer being treated, and the physical characteristics of the patient. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
  • the pharmaceutical compositions can be used alone, or in combination with other therapeutic or diagnostic agents.
  • compositions of the present invention can be administered to the patient in a variety of ways, including topically, parenterally, intravenously, subcutaneously, intramuscularly, colonically, rectally, nasally or intraperiotoneally, employing a variety of dosage forms.
  • the pharmaceutical compositions are administered parenterally, intravenously, or orally.
  • Such methods can also be used in testing the activity of test compounds in vivo.
  • compositions of the present invention are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art.
  • compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • Components in the formulation of a mouthwash or rinse include antimicrobials, surfactants, cosurfactants, oils, water and other additives such as sweeteners/flavoring agents known in the art.
  • the composition When administered by a drinking solution, the composition comprises one or more of the compounds of the present invention, dissolved in water, with appropriate pH adjustment, and with carrier. The compound may be dissolved in distilled water, tap water, spring water, and the like.
  • the pH can preferably be adjusted to between about 3.5 and about 8.5.
  • Sweeteners may be added, e.g., 1% (w/v) sucrose.
  • the formulations of this invention may be varied to include; (1) other acids and bases to adjust the pH; (2) other tonicity imparting agents such as sorbitol, glycerin and dextrose; (3) other antimicrobial preservatives such as other parahydroxy benzoic acid esters, sorbate, benzoate, propionate, chlorbutanol, phenylethyl alcohol, benzalkonium chloride, and mercurials; (4) other viscosity imparting agents such as sodium carboxymethylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, polyvinyl alcohol and other gums; (5) suitable absorption enhancers; (6) stabilizing agents such as antioxidants, like bisulfite and ascorbate, metal chelating agents such as sodium edetate and drug solubility enhancers such as polyethylene glycol
  • the present invention also provides methods for decreasing the toxicity to a patient of a cancer drug treatment regimen that includes 5-FU, or an analog or prodrug of 5-FU, to a cancer patient by adding 5,10-CH 2 -THFA to the drug regimen.
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof, and adding 5,10- CH 2 -THFA to the anticancer drug protocol to obtain an anticancer drug protocol having reduced toxicity to the patient.
  • the method for decreasing the toxicity of a cancer drug treatment that includes administration of 5-FU or an analogue or prodrug thereof comprises administering 5,10- 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU to reduce the toxicity of 5-FU.
  • administration of 5,10- CH 2 -THFA is before administration of 5-FU.
  • 5,10-CH 2 -THFA is administered to a patient receiving 5- FU to reduce hematological toxicity of 5-FU.
  • 5-FU and 5,10-CH 2 -THFA are administered to the patient in the absence of leucovorin (folinic acid, FA).
  • a cancer patient can be a patient with any type of cancer.
  • the patient in some preferred embodiments of the present invention in which 5,10-CH 2 -THFA is administered to a cancer patient receiving 5-FU, the patient has a tumor type that is currently treated with 5-FU, such as, for example, colorectal carcinoma, pancreatic cancer, breast cancer, head- and-neck cancer, esophageal, or stomach cancer.
  • 5-FU colorectal carcinoma
  • pancreatic cancer pancreatic cancer
  • breast cancer head- and-neck cancer
  • esophageal or stomach cancer.
  • the invention is based on the surprising result that 5,10-CH 2 -THFA, while increasing the efficacy of 5-FU in reducing the rate of tumor growth and increasing survivorship, also reduces the toxicity of 5-FU towards nontumor cells.
  • treatment with 5,10-CH 2 -THFA and 5-FU reduces tumor growth rate and increases survivorship of tumor-bearing animals with respect to treatment with either 5-FU alone, or 5-FU in combination with leucovorin (folinic acid), while demonstrating less toxicity to the animal than either treatment.
  • reduced the toxicity refers to reducing toxic systemic effects on the patient, or toxic effects on the noncancerous cells of the patient.
  • Toxicity can include, as nonlimiting examples, increased lacrimation; mucositis; esophagopharyngitis; neurological toxicity, such as parasthesias, insomnia, and dizziness; gastrointestinal toxicity, such as nausea, vomiting, and diarrhea; weight loss toxicity; cardiac toxicity; dermatological toxicity, including alopecia, sweating, and rashes; and hematological toxicity, such as, but not limited to, neutropenia, thrombocytopenia, lymphopenia, and leucopenia.
  • 5,10-CH 2 - THFA is administered in combination therapy with 5-FU to reduce the degree of hematological toxicity associated with 5-FU treatment.
  • administering 5,10- CH 2 -THFA along with 5-FU can reduce neutropenia, thrombocytopenia, lymphopenia, or leucopenia associated with chemotherapy regimens that include 5-FU, including but not limited to chemotherapy regimens that include 5-FU and leucovorin (folinic acid).
  • chemotherapy regimens that include 5-FU including but not limited to chemotherapy regimens that include 5-FU and leucovorin (folinic acid).
  • Some preferred treatments of cancer patients with 5-FU and 5,10-CH 2 -THFA are regimens using from 10 milligrams to 1 gram of 5,10- CH -THFA per m 2 , preferably from 20 milligrams to 500 milligrams of 5,10- CH 2 -THFA per m 2 , and more preferably from about 30 milligrams to about 250 milligrams of 5,10-CH 2 -THFA per m 2 .
  • a preferred dose of 5,10-CH 2 -THFA can be from about 30 to about 120 milligrams per m .
  • Dosage of 5- FU can be from about to about 25 milligrams to about 5 grams per 9 9 m , and is preferably from about 50 milligrams to 2.5 grams per m , and more preferably from about 100 milligrams to about 1 gram per m .
  • a preferred dose of 5- FU can be from about 250 to about 700 milligrams per m 2 .
  • 5-FU can be administered by any feasible means, including injection or TV feed.
  • a prodrug or analog of 5-FU is used in combination therapy rather than 5-FU itself.
  • 5-FU is converted to 5-fluoro-2'-deoxyuridylate (FdUMP) the inhibitor of thymidylate synthase.
  • FdUMP 5-fluoro-2'-deoxyuridylate
  • analog or prodrug of 5-FU is used to mean an analog or prodrug that can be directly or indirectly converted to an inhibitor of thymidylate synthase, such as FdUMP.
  • One prodrug of 5-FU that can be used in the methods of the present invention is N4-pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
  • the method of the present invention comprises administering N4- pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine); 5,10-CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of capecitabine can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the of daily dosage of capecitabine can be from about 500 mg to about 7500 mg per m 2 , preferably from about 1000 mg to about 5000 mg per m 2 , and more preferably from about 1500 mg to about 3000 mg per m .
  • the dose can be divided into one to six (preferably two) administrations per day.
  • the foregoing are general guidelines only that can be expanded or altered based on for example, cancer type and grade, patient age, health status, and sex, the particular drugs used in combination, the route and frequency of administration, and experimental and clinical findings using a multidrug combination.
  • Capecitabine can be administered by any feasible means including injection, IV feed, or in an oral formulation.
  • An analog combination that can be used in the methods of the present invention is
  • the method of the present invention comprises administering UFT; 5,10- CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of UFT can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the daily dosage of UFT can be from about 50 mg to about 3000 mg per m 2 , preferably from about 100 mg to about 2000 mg per m 2 , and more preferably from about 200 mg to about 1000 mg per m 2 .
  • Anticancer regimens that include UFT can optionally also include calcium folinate administered with UFT.
  • UFT can be administered by any feasible means, including injection, IV feed, or in an oral formulation.
  • Some examples of anticancer drug protocols that use capecitabine are described in Blum JL, et al. "Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.” J Clin Oncol 1999; 17:485-93; in Hoff et al.
  • the present invention includes administering 5,10-CH 2 -THFA in protocols that include capecitabine to reduce toxicity of capecitabine treatment.
  • one protocol includes administering capecitabine (1000- 1250 mg per m 2 ) twice daily for two weeks, followed by a one week rest period, and then followed by further three week cycles.
  • 5,10-CH 2 -THFA can be added to protocols such as these, for example, and the protocols can be optimized based on clinical trials for toxicity and efficacy.
  • the present invention includes methods for decreasing the toxicity of an anticancer treatment that comprises administering 5-FU or an analog or prodrug of 5-FU and an additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by co-administering 5,10-5,10-CH 2 -THFA.
  • the method includes: obtaining an anticancer drug protocol that comprises 5 -fluorouracil or an analogue or prodrug thereof and at least one additional anticancer drug, and adding 5,10- CH 2 -THFA to the anticancer drug protocol to obtain an anticancer drug protocol having reduced toxicity to the patient.
  • An additional anticancer drug can be any type of anticancer drug, including without limitation, a topoisomerase inhibitor (e.g., irinotecan, topotecan), an antimetabolite drug (e.g., methotrexate, gemcitabine), a 5 -fluorouracil modulator, an alkylating agent (e.g., cyclophosphamide, carmustine), a nucleic acid biosynthesis inhibitor (e.g., mitomycin, doxorubicin, cisplatin, oxaliplatin, carboplatin), a microtubule disrupting drug (e.g., paclitaxel, docetaxel, vinolrebine, vincristine), a hormone blocking drug (e.g., tamoxifen), a kinase inhibitor, including but not limited to an inhibitor of receptor or nonreceptor tyrosine kinases (e.g., Iressa, Tarceva, SU54
  • Anticancer drugs can also be a drug under investigation for potential anti- cancer activity, such as those listed in Table 1.
  • Anti-cancer drugs include monoclonal antibodies, such as but not limited to monoclonal antibodies that bind cytokines, hormones, or hormone receptors (e.g., antibodies that block activation of EGF or VEGF growth factors, such as Avastin, erbutux, herceptin), etc.
  • the methods of the present invention include methods in which more than one additional anticancer drug is used in combination with 5-FU.
  • the method for decreasing the toxicity of a cancer drug treatment that includes administration of 5-FU or an analogue or prodrug thereof and an additional anticancer drug comprises administering 5,10- 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU (or an analogue or prodrug thereof).
  • administration of 5,10-CH 2 -THFA is before administration of 5-FU.
  • An additional anticancer drug can be administered before, after, or concurrent with administration of 5-FU.
  • Dosage for the one or more additional anticancer drugs used in a multidrug regimen of the present invention can also be determined by studies using escalating dosages and monitoring of toxicity and efficacy.
  • a number of chemotherapy protocols that combine 5-FU with one or more anticancer drugs are known in the field of cancer therapy.
  • anticancer protocols that include 5-FU in combination with one or more additional drugs include but are not limited to therapies for breast cancer that include cyclophosphamide, epirubicin, and fluorouracil (see, for example, Levine MN, Bramwell VH, Pritchard KI et al.
  • the present invention includes the addition of 5,10-CH 2 -THFA to chemotherapy regimens such as these to reduce the toxicity of the chemotherapy regimens.
  • Another example of an anticancer protocol to which 5,10-CH 2 -THFA can be added to reduce the toxicity of treatment is a protocol for the treatment of head-and-neck cancer that includes the use of mitomycin C and fluorouracil as disclosed in Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I.
  • anticancer protocols that combine 5-FU with mitomycin C, such as that disclosed in Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I.
  • anticancer treatment protocols include radiation therapy in addition to chemotherapy.
  • the present invention includes methods of decreasing the toxicity of a protocol that includes analogs or prodrugs of 5-FU and an additional anticancer drug (other than a folate cofactor of thymidylate synthase) by co-administering 5,10-CH 2 -THFA.
  • additional anticancer drug other than a folate cofactor of thymidylate synthase
  • Anticancer protocols to which 5,10-CH 2 -THFA can be added to reduce the toxicity of treatment can be obtained from any reputable source, including the scientific and medical literature, and the resources of hospitals, cancer centers, and clinics. It is within the scope of the invention to modify the dosages and schedules of either or both of 5-FU, 5,10-CH 2 -THFA, and, where relevant, one or more additional anticancer drugs in reducing the toxicity of a protocol by including administration of 5,10-CH 2 -THFA.
  • Some preferred embodiments of this aspect of the present invention include methods for reducing the toxicity of an anticancer drug regimen that includes 5-FU (or an analog or prodrug thereof) and a folate cofactor of thymidylate synthase in which 5,10- CH 2 -THFA is substituted for leucovorin as the folate cofactor for thymidylate synthase.
  • the methods comprise: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof and leucovorin; and substituting 5,10-CH -THFA for leucovorin in the anticancer drug protocol.
  • the present invention includes methods for decreasing toxicity of an anticancer drug regimen that includes an analog or prodrug of 5-FU, such as, but not limited to, capecitabine or UFT, and leucovorin, where toxicity of the regimen is decreased by substituting 5, 10-CH 2 -THFA for leucovorin in the regimen.
  • the present invention includes methods for decreasing the toxicity of an anticancer treatment that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the drug regimen.
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof; leucovorin; and at least one additional anticancer drug; and substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol.
  • 5,10-CH 2 - THFA can substitute for leucovorin in a range of current chemotherapy regimens.
  • current drugs commonly used in combination with 5-FU plus leucovorin are Irinotecan (CPT-11), Oxaliplatin, gemcitabine, mitomycin C, levamisole, and vinorelbine.
  • the present invention includes treatments that substitute 5,10-CH 2 - THFA for leucovorin in these regimens.
  • Substitution of 5,10-CH 2 -THFA for leucovorin can provide equivalent or enhanced therapeutic effects with reduced toxicity.
  • current drug combination regimens in which 5,10-CH -THFA can substitute for leucovorin include the following protocols used in the treatment of colorectal cancer:
  • AIO regimen folinic acid, 5-FU, Irinotecan: ⁇ Irinotecan (100 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (500 mg/m 2 ) as a 2-hour infusion day 1; followed by 5-FU (2,000 mg/m 2 ) intravenous (IN) bolus via ambulatory pump over 24 hours weekly x 4 every 52 weeks.
  • FOLFOX4 regimen oxaliplatin, leucovorin, 5-FU: ⁇ Oxaliplatin (85 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (200 mg/m 2 ) as a 2-hour infusion days 1 and 2; followed by a loading dose of 5-FU (400 mg/m 2 ) IV bolus, then 5-FU (600 mg/m 2 ) via ambulatory pump over 22 hours days 1 and 2 every 2 weeks.
  • FOLFOX6 regimen oxaliplatin, leucovorin, 5-FU: ⁇ Oxaliplatin (85-100 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (400 mg/m 2 ) as a 2-hour infusion day 1; followed by a loading dose of 5-FU (400 mg/m 2 ) IV bolus on day 1, then 5-FU (2,400-3,000 mg/m 2 ) via ambulatory pump over 46 hours every 2 weeks.
  • FOLFIRI regimen folinic acid, 5-FU, Irinotecan: ⁇ Irinotecan (180 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (400 mg/m 2 ) as a 2-hour infusion day 1; followed by a loading dose of 5-FU (400 mg/m 2 ) TV bolus on day 1, then 5-FU (2,400-3,000 mg/m 2 ) via ambulatory pump over 46 hours every 2 weeks.
  • IFL (or Saltz) regimen (Irinotecan, 5-FU, leucovorin) - IIrriinnootteeccaann ((112255 mmgg//mm 2z )),, 55--FFUU ((550000 mmgg//mm 2 )) : IV bolus, and leucovorin (20 mg/m 2 ) IV bolus weekly for 4 out of 6 weeks
  • Other regimens in which 5,10-CH 2 -THFA can substitute for leucovrin include in combination with 5-FU and at least one other anticancer drug include, for example, FOLFUGEM 1 ((leucovorin 400 mg/m2 combined with 5-flurorouracil (FU) bolus 400 mg/m2 then 5-FU 2-3 g/m.2/46 hours and gemcitabine 1000 mg/m2 in 30 min) and FOLFUGEM 2 (leucovorin 400 mg/m2 in 2 hours followed by 5-FU 1000 mg/m2 in 22 hours, then gemcitabine 800 mg/m2 (10 mg/m2/min) with cycles every 14 days) used to treat pancreatic cancer (as disclosed in Andre et al.
  • FOLFUGEM 1 (leucovorin 400 mg/m2 combined with 5-flurorouracil (FU) bolus 400 mg/m2 then 5-FU 2-3 g/m.2/46 hours and gemcitabine 1000 mg/m2 in 30 min)
  • FOLFUGEM 2 leucovorin 400
  • 5,10-CH 2 -THFA can also be substituted for leucovorin in protocols in which 5-FU and leucovorin are used in combination with more than one additional anticancer drug.
  • Other uses of 5,10-CH 2 -THFA are in combination therapy with new classes of biologic anti-tumor reagents, such as monoclonal antibodies with anti-tumor activity. Examples of antibodies that might be combined with 5, 10-CH 2 -THFA (preferably with 5- FU) include anti-VEGF antibody (e.g.
  • the lower toxicity profile of 5,10-CH 2 -THFA can allow use of either increased concentrations of drugs (e.g. 5-FU) or prolonged dosing periods. In turn this may increase drug efficacy.
  • the present invention also includes the use of 5,10-CH 2 -THFA in place of leucovorin (leucovorin) in therapies that do not use 5-FU.
  • 5,10-CH 2 -THFA can be used for methotrexate rescue therapy. This mode of therapy currently uses leucovorin. V.
  • the present invention also provides methods for increasing the efficacy of an anticancer drug treatment regimen that includes administration of 5- 5-FU or an analog or prodrug of 5-FU to a cancer patient by co-administering 5,10-CH 2 -THFA.
  • the method comprises: obtaining an anticancer drug regimen that comprises 5 -fluorouracil or an analogue or prodrug thereof, and adding 5,10-CH 2 -THFA to the drug regimen to increase the efficacy of the anticancer drug regimen.
  • 5-FU and 5,10-CH 2 -THFA are administered to the patient in the absence of leucovorin (folinic acid, FA).
  • the method for increasing the efficacy of a cancer drug treatment that includes administration of 5- FU or an analogue or prodrug thereof comprises administering 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU to reduce the toxicity of 5-FU.
  • administration of 5,10-CH 2 -THFA is before administration of 5-FU.
  • the invention provides methods for increasing survivorship of a cancer patient by adding 5,10-CH 2 -THFA to an anticancer drug regimen administered to the patient that includes 5-FU or an analog or prodrug of 5-FU.
  • the method comprises: obtaining an anticancer drug protocol that comprises 5 -fluorouracil or an analogue or prodrug thereof, adding 5,10-CH 2 -THFA to the anticancer drug protocol; and treating a cancer patient with the modified anticancer drug protocol.
  • the method includes administering 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU.
  • 5-FU and 5,10-CH 2 -THFA are administered to the patient in the absence of leucovorin (folinic acid, FA).
  • a cancer patient can be a patient with any type of cancer.
  • the patient has a tumor type that is currently treated with 5-FU, such as, for example, colorectal carcinoma, pancreatic cancer, breast cancer, head- and-neck cancer, or stomach cancer.
  • Efficacy of an anticancer drug regimen can be determined by methods such as but not limited to: tumor size after treatment, the rate of tumor growth (or shrinkage), detection of cancer cells or markers, the length of remission after treatment, and the survivorship of the cancer patients treated with the regimen.
  • Some preferred treatments of cancer patients with 5-FU and 5,10-CH 2 -THFA are regimens using from 10 milligrams to 1 gram of 5,10- CH 2 -THFA per m 2 , preferably from 20 milligrams to 500 milligrams of 5,10- CH 2 -THFA per m 2 , and more preferably from about 30 milligrams to about 250 milligrams of 5,10-CH 2 -THFA per m 2 .
  • a preferred dose of 5,10-CH 2 -THFA can be from about 30 to about 120 milligrams per m .
  • the foregoing are general guidelines only that can be expanded or altered based on for example, cancer type and grade, patient age, health status, and sex, the particular drugs used in combination, the route and frequency of administration, and experimental and clinical findings using a multidrug combination.
  • Dosage of 5- FU can be from about 25 milligrams to about 5 grams per m 2 , and is preferably from about 50 milligrams to 2.5 grams per m 2 , and more preferably from about 100 milligrams to about 1 gram per m 2 .
  • a preferred dose of 5- FU can be from about 250 to about 700 milligrams per m .
  • the foregoing are general guidelines only that can be expanded or altered based on for example, cancer type and grade, patient age, health status, and sex, the particular drugs used in combination, the route and frequency of administration, and experimental and clinical findings using a multidrug combination.
  • 5-FU can be administered by any feasible means, including injection or IV feed.
  • a prodrug or analog of 5-FU is used in combination therapy rather than 5-FU itself.
  • 5-FU is converted to 5-fluoro-2'-deoxyuridylate (FdUMP) the inhibitor of thymidylate synthase.
  • FdUMP 5-fluoro-2'-deoxyuridylate
  • analog or prodrug of 5-FU is used to mean an analog or prodrug that can be directly or indirectly converted to an inhibitor of thymidylate synthase, such as FdUMP.
  • One prodrug of 5-FU that can be used in the methods of the present invention is N4-pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
  • the method of the present invention comprises administering N4- pentoxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine); 5,10-CH -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of capecitabine can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the of daily dosage of capecitabine can be from about 500 mg to about 7500 9 9 mg per m , preferably from about 1000 mg to about 5000 mgs per m , and more preferably from about 1500 mg to about 3000 mg per m 2 .
  • the dose can be divided into one to six (preferably two) administrations per day.
  • the foregoing are general guidelines only that can be expanded or altered based on for example, cancer type and grade, patient age, health status, and sex, the particular drugs used in combination, the route and frequency of administration, and experimental and clinical findings using a multidrug combination.
  • Capecitabine can be administered by any feasible means including injection, IV feed, or in an oral formulation.
  • An analog combination that can be used in the methods of the present invention is Tegafur (TF) and uracil (U) used in a 1:4 combination known as UFT.
  • the method of the present invention comprises administering UFT; 5,10- CH 2 -THFA; and at least one additional anticancer drug to a patient with cancer.
  • the dosage of UFT can be determined by skilled clinicians and depends in part on the frequency of administration.
  • the daily dosage of UFT can be from about 50 mg to about 3000 mg per m 2 , preferably from about 100 mg to about 2000 mg per m 2 , and more preferably from about 200 mg to about 1000 mg per m .
  • Anticancer regimens that include UFT can optionally also include calcium folinate administered with UFT.
  • UFT can be administered by any feasible means, including injection, IV feed, or in an oral formulation.
  • Some examples of anticancer drug protocols that use capecitabine are described in Blum JL, et al. "Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.” J Clin Oncol 1999; 17:485-93; in Hoff et al.
  • the present invention includes administering 5,10-CH 2 -THFA in protocols that include capecitabine to improve efficacy of treatment.
  • one protocol includes administering capecitabine (1000- 1250 mg per m 2 ) twice daily for two weeks, followed by a one week rest period, and then followed by further three week cycles.
  • 5,10-CH 2 -THFA can be added to protocols such as these, for example, and the protocols can be optimized based on clinical trials for toxicity and efficacy.
  • the present invention includes methods for increasing the efficacy of an anticancer treatment that comprises administering 5-FU or an analog or prodrug of 5-FU and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by co-administering 5,10- 5,10-CH 2 -THFA.
  • the method includes: obtaining an anticancer drug protocol that comprises 5 -fluorouracil or an analogue or prodrug thereof and at least one additional anticancer drug, and adding 5,10-methylene tetrahydrofolate to the anticancer drug protocol to obtain an anticancer drug protocol having increased efficacy.
  • the method for increasing the efficacy of a cancer drug treatment that includes administration of 5-FU or an analogue or prodrug thereof and an additional anticancer drug comprises administering 5,10- 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU (or an analogue or prodrug thereof).
  • administration of 5,10-CH 2 -THFA is before administration of 5-FU.
  • An additional anticancer drug can be administered before, after, or concurrent with administration of 5-FU.
  • the invention provides methods for increasing survivorship of a cancer patient by adding 5,10- 5,10-CH 2 -THFA to an anticancer drug regimen administered to the patient that includes 5- 5-FU or an analog or prodrug of 5-FU, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase).
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof and at least one additional anticancer drug; adding 5,10-CH 2 -THFA to the anticancer drug protocol; and treating a cancer patient with the modified anticancer drug protocol.
  • the method includes administering 5,10- CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU.
  • 5-FU and 5,10-CH 2 -THFA are administered to the patient in the absence of leucovorin (folinic acid, FA).
  • An additional anticancer drug can be administered before, after, or concurrent with administration of 5-FU.
  • Dosage for the one or more additional anticancer drugs used in a multidrug regimen of the present invention can also be determined by studies using escalating dosages and monitoring of toxicity and efficacy. In determining dosages of an anticancer . drug to be used in combination therapy that have been used independently in chemotherapy regimens, practitioners can take into account dosages of drugs used in established chemotherapy regimens.
  • a number of chemotherapy protocols that combine 5-FU with one or more anticancer drugs are known in the field of cancer therapy.
  • anticancer protocols that include 5-FU in combination with one or more additional drugs include but are not limited to therapies for breast cancer that include cyclophosphamide, epirubicin, and fluorouracil (see, for example, Levine MN, Bramwell VH, Pritchard KI et al.
  • Another example of an anticancer protocol to which 5, 10-CH 2 -THFA can be added to increase the efficacy of treatment is a protocol for the treatment of head-and- neck cancer that includes the use of mitomycin C and fluorouracil as disclosed in Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I.
  • anticancer protocols that combine 5-FU with mitomycin C, such as that disclosed in Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I. "A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 -fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.”
  • the present invention includes methods of increasing the efficacy of a protocol that includes analogs or prodrugs of 5-FU and an additional anticancer drug (other than a folate cofactor of thymidylate synthase) by co-administering 5,10-CH 2 -THFA.
  • additional anticancer drug other than a folate cofactor of thymidylate synthase
  • anticancer regimens that include capecitabine and docetaxel are disclosed in O'Shaughnessy J, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pre-treated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23, herein incorporated by reference, particularly for disclosure of anticancer protocols using capecitabine.
  • 5,10-CH 2 -THFA can also be added to protocols that include tegafur-uracil (UFT) in combination with an additional cancer drug, for example, protocols that include oxaliplatin, as disclosed in Feliu J. et al. "Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.” Br. J. Cancer 2004 91: 1758-62; herein incorporated by reference, particularly for disclosure of anticancer protocols using UFT.
  • UFT tegafur-uracil
  • Anticancer protocols to which 5,10-CH 2 -THFA can be added to increase the efficacy of treatment can be obtained from any reputable source, including the scientific and medical literature, and the resources of hospitals, cancer centers, and clinics. It is within the scope of the invention to modify the dosages and schedules of either or both of 5-FU, 5,10-CH 2 -THFA, and, where relevant, one or more additional anticancer drugs in increasing the efficacy of a protocol by including administration of 5,10-CH 2 -THFA. Such modifications can be made by trained clinicians that monitor patient response to treatment according to accepted medical practices.
  • the present invention includes methods of increasing the efficacy of an anticancer drug regimen that includes 5-FU and a folate cofactor of thymidylate synthase in which 5,10-CH 2 -THFA is substituted for leucovorin as the thymidylate synthase cofactor.
  • the invention includes methods of increasing the efficacy of an anticancer drug regimen, in which the anticancer drug regimen includes 5- FU and a folate cofactor of thymidylate synthase and efficacy is increased by substituting 5,10-CH 2 -THFA for leucovorin as the thymidylate synthase cofactor.
  • the method comprises: obtaining an anticancer drug regimen that comprises 5-FU or an analogue or prodrug thereof, leucovorin, and an additional anticancer drug; and substituting 5,10- CH 2 -THFA for leucovorin in the drug regimen to obtain a drug regimen with improved efficacy.
  • the invention provides methods for increasing survivorship of a cancer patient by substituting 5,10- 5,10-CH 2 -THFA for leucovorin in an anticancer drug regimen administered to the patient that includes 5-FU or an analog or prodrug of 5- FU.
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof and leucovorin; substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol; and treating a cancer patient with the modified anticancer drug protocol.
  • the method includes administering 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU.
  • the present invention includes methods for increasing the efficacy of an anticancer drug regimen that includes an analog or prodrug of 5-FU, such as, but not limited to, capecitabine or UFT, and leucovorin, where efficacy of the regimen is increased by substituting 5,10-CH 2 -THFA for leucovorin in the regimen.
  • the present invention also provides methods for increasing survivorship of a cancer patient by substituting 5,10-CH -THFA for leucovorin in an anticancer drug regimen administered to the patient that includes an analog or prodrug of 5-FU, such as but not limited to capecitabine or UFT.
  • the present invention includes methods for increasing the efficacy of an anticancer treatment that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase) to a patient with cancer by substituting 5,10- 5,10-CH 2 -THFA for leucovorin in the drug regimen.
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof; leucovorin; and at least one additional anticancer drug; and substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol.
  • the invention provides methods for increasing survivorship of a cancer patient by substituting 5,10- 5,10-CH 2 -THFA for leucovorin in an anticancer drug regimen administered to the patient that includes 5-FU or an analog or prodrug of 5- FU, and at least one additional anticancer drug (other than 5-FU or a folate cofactor of thymidylate synthase).
  • the method comprises: obtaining an anticancer drug protocol that comprises 5-FU or an analogue or prodrug thereof, leucovorin, and at least one additional anticancer drug; substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol; and treating a cancer patient with the modified anticancer drug protocol.
  • the method includes administering 5,10-CH 2 -THFA to the patient before, after, or concurrent with the administration of 5-FU.
  • An additional anticancer drug can be administered before, after, or concurrent with administration of 5-FU. Because of the anti-tumor activity and decreased systemic toxicity of 5,10-CH 2 - THFA compared to leucovorin, and because of the similar chemical and metabolic pathways of leucovorin and 5,10-CH 2 -THFA, the inventors contemplate that 5,10-CH 2 - THFA can substitute for leucovorin in a range of current chemotherapy regimens.
  • Examples of current drugs commonly used in combination with 5-FU plus leucovorin are Irinotecan (CPT-11), Oxaliplatin, gemcitabine, levamisole, mitomycin C, and vinorelbine.
  • the present invention includes treatments that substitute 5,10-CH 2 -THFA for leucovorin in these regimens. Substitution of 5,10-CH 2 -THFA for leucovorin can provide enhanced therapeutic effects with reduced toxicity.
  • current drug combination regiments that 5,10-CH 2 -THFA can substitute for leucovorin include:
  • AIO regimen folic acid, 5-FU, Irinotecan: ⁇ Irinotecan (100 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (500 mg/m 2 ) as a 2-hour infusion day 1; followed by 5-FU (2,000 mg/m 2 ) intravenous (IV) bolus via ambulatory pump over 24 hours weekly x 4 every 52 weeks.
  • FOLFOX4 regimen oxaliplatin, leucovorin, 5-FU: ⁇ Oxaliplatin (85 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (200 mg/m ) as a 2-hour infusion days 1 and 2; followed by a loading dose of 5-FU (400 mg/m 2 ) IV bolus, then 5-FU (600 mg/m 2 ) via ambulatory pump over 22 hours days 1 and 2 every 2 weeks.
  • FOLFOX6 regimen oxaliplatin, leucovorin, 5-FU: ⁇ Oxaliplatin (85-100 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (400 mg/m ) as a 2-hour infusion day 1 ; followed by a loading dose of 5-FU (400 mg/m 2 ) TV bolus on day 1, then 5-FU (2,400-3,000 mg/m 2 ) via ambulatory pump over 46 hours every 2 weeks.
  • FOLFIRI regimen folic acid, 5-FU, Irinotecan: ⁇ Irinotecan (180 mg/m 2 ) as a 2-hour infusion day 1; leucovorin (400 mg/m 2 ) as a 2-hour infusion day 1; followed by a loading dose of 5-FU (400 mg/m 2 ) TV bolus on day 1, then 5-FU (2,400-3,000 mg/m 2 ) via ambulatory pump over 46 hours every 2 weeks.
  • IFL (or Saltz) regimen (Irinotecan, 5-FU, leucovorin): ⁇ Irinotecan (125 mg/m 2 ), 5-FU (500 mg/m 2 ) TV bolus, and leucovorin (20 mg/m 2 ) IV bolus weekly for 4 out of 6 weeks.
  • Other regimens in which 5,10-CH 2 -THFA can substitute for leucovrin include in combination with 5-FU and at least one other anticancer drug include, for example, FOLFUGEM 1 ((leucovorin 400 mg/m 2 combined with 5-flurorouracil (FU) bolus 400 mg/m 2 then 5-FU 2-3 g/m 2 /46 hours and gemcitabine 1000 mg/m 2 in 30 min) and FOLFUGEM 2 (leucovorin 400 mg/m 2 in 2 hours followed by 5-FU 1000 mg/ m 2 in 22 hours, then gemcitabine 800 mg/m 2 (10 mg/m 2 /min) with cycles every 14 days) used to treat pancreatic cancer (as disclosed in Andre et al.
  • FOLFUGEM 1 (leucovorin 400 mg/m 2 combined with 5-flurorouracil (FU) bolus 400 mg/m 2 then 5-FU 2-3 g/m 2 /46 hours and gemcitabine 1000 mg/m 2 in 30 min)
  • FOLFUGEM 2 le
  • 5,10-CH 2 -THFA are in combination therapy with new classes of biologic anti-tumor reagents, such as monoclonal antibodies with anti-tumor activity.
  • biologic anti-tumor reagents such as monoclonal antibodies with anti-tumor activity.
  • antibodies that might be combined with 5, 10-CH 2 -THFA include anti-VEGF antibody (e.g. Avastin, Bevacuzimab) and anti-EGF receptor (e.g. Erbitux, cetuximab, herceptin).
  • anti-VEGF antibody e.g. Avastin, Bevacuzimab
  • anti-EGF receptor e.g. Erbitux, cetuximab, herceptin
  • the inventors contemplate that at least one of the one or more additional anticancer drugs can be administered at an increased dosage relative to the dosage typically used for the additional anti-cancer drug in a regimen that includes 5-FU.
  • the invention includes a method of increasing the efficacy of an anticancer drug protocol that includes 5-FU and at least one additional anticancer drug (other than 5-FU or an analog or prodrug thereof, or a folate cofactor of thymidylate synthase), by adding 5,10-CH 2 - THFA to the drug regimen and increasing the dosage of at least one of the one or more additional anticancer drugs.
  • the method includes: obtaining an anticancer drug protocol that includes 5-FU or an analog or prodrug of 5-FU and at least one additional anticancer drug (other than 5-FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase); adding 5,10- CH 2 -THFA to the anticancer drug protocol; and increasing the dosage of the one or more additional anticancer drugs in the anticancer drug protocol.
  • adding 5,10-CH 2 -THFA to the anticancer regimen while increasing the dosage of an additional anticancer drug used in the regimen can increase the efficacy of a treatment without prohibitively increasing toxicity.
  • the invention includes methods of increasing the survivorship of a cancer patient by adding 5,10- CH 2 -THFA to an anticancer regimen that includes 5- FU and one or more additional anticancer drugs (other than 5-FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase) and increasing the dosage of at least one of the one or more additional anticancer drugs used in the regimen.
  • additional anticancer drugs other than 5-FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase
  • a number of chemotherapy protocols that combine 5-FU with one or more anticancer drugs are known in the field of cancer therapy.
  • protocols referenced in this application include protocols in which 5-FU is combined with cyclophosphamide, epirubicin, docorubicin, carboplatin, or mitomycin C. These examples are in no way limiting to the scope of the invention.
  • Other protocols known or used in the future in the field of cancer therapy that use these or other anti-cancer drugs in combination with 5-FU can also be modified by including 5,10-CH 2 -THFA and increasing the dosage of at least one of the one or more additional anticancer drugs.
  • the present invention includes methods of increasing the efficacy of a protocol that includes analogs or prodrugs of 5-FU and at least one additional anticancer drug (other than a folate cofactor of thymidylate synthase) by co-administering 5,10-CH 2 - THFA.
  • An anticancer regimen that includes capecitabine and docetaxel, and an anticancer regimen that includes UFT and oxaliplatin, are referenced herein as nonlimiting examples of protocols that can be modified including 5,10-CH -THFA and increasing the dosage of the additional anticancer drug.
  • the foregoing references to protocols are examples only, and are not intended to limit the invention in any way.
  • Anticancer protocols to which 5,10-CH 2 -THFA can be added can be obtained from any reputable source, including the scientific and medical literature, and the resources of hospitals, cancer centers, and clinics. Dose escalation studies can be performed according to established protocols that monitor toxicity and efficacy. It is within the scope of the invention to modify the dosages and schedules of either or both of 5-FU, 5,10-CH 2 -THFA, as well as one or more additional anticancer drugs, in optimizing anticancer treatment protocols. Such modifications can be made by trained clinicians that monitor patient response to treatment according to accepted medical practices.
  • the invention provides a method of increasing the efficacy of an anticancer drug protocol of an anticancer drug protocol that comprises 5- FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug by replacing leucovorin with 5,10-CH 2 -THFA in the protocol and increasing the dosage of at least one additional anticancer drug.
  • the method includes: obtaining an anticancer drug protocol that includes 5-FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than 5-FU or an analog or prodrug of 5- FU or a folate cofactor of thymidylate synthase); substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol; and increasing the dosage of the at least one additional anticancer drug in the anticancer drug protocol.
  • substituting 5,10-CH 2 -THFA for leucovorin in the anticancer while increasing the dosage of an additional anticancer drug used in the regimen can increase the efficacy of a treatment without prohibitively increasing toxicity.
  • the invention includes methods of increasing the survivorship of a cancer patient by substituting 5,10-CH 2 -THFA for leucovorin in an anticancer regimen that includes 5-FU and one or more additional anticancer drugs (other than 5-FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase) and increasing the dosage of at least one of the one or more additional anticancer drugs used in the regimen.
  • an anticancer regimen that includes 5-FU and one or more additional anticancer drugs (other than 5-FU or an analog or prodrug of 5-FU or a folate cofactor of thymidylate synthase) and increasing the dosage of at least one of the one or more additional anticancer drugs used in the regimen.
  • a number of chemotherapy protocols that combine 5-FU and leucovorin with one or more anticancer drugs are known in the field of cancer therapy.
  • protocols referenced in this application include protocols in which 5-FU is combined gemcitabine, vinorelbine, levamisole, irinotecan, oxaliplatin, or mitomycin C. These examples are in no way limiting to the scope of the invention.
  • Other protocols known or used in the future in the field of cancer therapy that use these or other anti-cancer drugs in combination with 5-FU and leucovorin can also be modified by substituting 5,10-CH 2 -THFA for leucovorin and increasing the dosage of at least one of the one or more additional anticancer drugs.
  • the present invention includes methods of increasing the efficacy of a protocol that includes analogs or prodrugs of 5-FU, leucovorin, and at least one additional anticancer drug (other than a folate cofactor of thymidylate synthase) by substituting 5,10-CH 2 -THFA and increasing the dosage of an additional anticancer drug.
  • additional anticancer drug other than a folate cofactor of thymidylate synthase
  • Dose escalation studies can be performed according to established protocols that monitor toxicity and efficacy. It is within the scope of the invention to modify the dosages and schedules of either or both of 5-FU, 5,10-CH 2 - THFA, as well as one or more additional anticancer drugs, in optimizing anticancer treatment protocols. Such modifications can be made by trained clinicians that monitor patient response to treatment according to accepted medical practices. The inventors also contemplate that 5-FU can be administered at an increased dosage relative to the dosage typically used in combination therapy when 5,10-CH 2 - THFA is added to the drug regimen.
  • the invention includes a method of increasing the efficacy of an anticancer drug protocol by increasing the dosage of 5-FU used in a drug regimen for treating cancer that includes 5-FU (or an analog or prodrug thereof) and an additional anticancer drug (other than a folate cofactor of thymidylate synthase) by adding 5,10-CH 2 -THFA to the drug regimen.
  • the method includes: obtaining an anticancer drug protocol that includes 5-FU or an analog or prodrug of 5-FU and at least one additional anticancer drug (other than a folate cofactor of thymidylate synthase); adding 5,10-CH 2 -THFA to the anticancer drug protocol; and increasing the dosage of 5- FU in the anticancer drug protocol.
  • the invention provides a method of increasing the dose of 5-FU in an anticancer drug protocol that comprises 5-FU or an analog or prodrug of 5-FU, leucovorin, and an additional anticancer drug by replacing leucovorin with 5,10- CH 2 -THFA.
  • the method includes: obtaining an anticancer drug protocol that includes 5- FU or an analog or prodrug of 5-FU, leucovorin, and at least one additional anticancer drug (other than a folate cofactor of thymidylate synthase); substituting 5,10-CH 2 -THFA for leucovorin in the anticancer drug protocol; and increasing the dosage of 5-FU (or an analog or prodrug thereof) in the anticancer drug protocol.
  • substituting 5,10-CH 2 -THFA for leucovorin in the anticancer while increasing the dosage of 5-FU used in the regimen can increase the efficacy of a treatment without prohibitively increasing toxicity.
  • Example 1 Nude Mouse Study on Colorectal Tumor HT-29 Treatment with 5-FU, 5,10-CH 2 -THFA, Leucovorin, anti-VEGF, and Oxaliplatin.
  • mice Nude (nu/nu) mice were obtained from Charles River Laboratories. Mice were 6- 8 weeks old at the start of all studies. Mice were maintained in isolated, hepa-f ⁇ lter ventilated cages with 4 mice per cage at LAB International's vivarium (San Diego, CA).
  • the human colon carcinoma HT-29 was obtained from American Tissue Culture
  • ATCC American Type Culture Collection
  • Drugs 5 -Fluorouracil 5-FU was obtained from Calbiochem.
  • a monoclonal antibody to vascular endothelial growth factor (anti- VEGF) was either obtained from R&D Systems (clone 26503 recognizing the human VEGF isoform 165) or Genentech (Avastin).
  • HT-29 Colorectal Carcinoma Nude Mouse Study #1 HT-29 cells were prepared for injection as follows. Confluent tissue culture flasks of HT-29 cells were washed once with PBS followed by cell detachment with trypsin. Detached cells were then washed once in DMEM-10 followed by one wash with PBS. Finally, cells were resuspended at 2xl0 7 cells/ml in PBS. Nude mice (nu/nu) were inoculated subcutaneously with 100 microliters (2xl0 6 cells) of HT-29 cells using a 28 gauge insulin needle/syringe.
  • mice treated with 5-FU/5,10-CH 2 -THFA were still alive (Figure 5). This survival was significantly longer than mice treated with only 5-FU (25%, p ⁇ 0.05, Logrank test).
  • 5-FU/5,10-CH 2 -THFA treated mice 5-FU/5,10-CH 2 -THFA/anti-VEGF treated mice also survived longer (57%) than all other treatment groups.
  • the lack of protection of mice treated with 5-FU/5,10-CH 2 -THFA /Oxaliplatin (25%) ( Figure 6) compared to other treatment groups can most likely be attributed to the apparent resistance of the HT-29 tumor to oxaliplatin ( Figure 3).
  • 5- FU/5,10-CH 2 -THFA treatment provided the greatest survival benefit.
  • Example 2 Nude Mouse Study on Colorectal Tumor HT-29 Treatment with 5-FU, 5,10-CH 2 -THFA, FA, and anti-VEGF.
  • mice Nude (nu/nu) mice were obtained from Charles River Laboratories. Mice were 6- 8 weeks old at the start of all studies. Mice were maintained in isolated, hepa-filter ventilated cages with 4 mice per cage at LAB International's vivarium (San Diego, CA). Cell Lines The human colon carcinoma HT-29 was obtained from American Tissue Culture
  • ATCC American Type Culture Collection
  • 5-Fluorouracil was obtained from Calbiochem.
  • Leucovorin leucovorin
  • oxaliplatin obtained from Sigma- Aldrich.
  • 5,10 methylenetetrahydofolate was manufactured by Eprova AG.
  • a monoclonal antibody to vascular endothelial growth factor (anti-VEGF) was either obtained from R&D Systems (clone 26503 recognizing the human VEGF isoform 165) or Genentech (Avastin).
  • HT-29 Colorectal Carcinoma Nude Mouse Study #2 HT-29 cells were prepared for injection as follows. Confluent tissue culture flasks of HT-29 cells were washed once with PBS followed by cell detachment with trypsin. Detached cells were then washed once in DMEM- 10 followed by one wash with PBS. Finally, cells were resuspended at lxl 0 7 cells/ml in PBS. Nude mice (nu/nu) were inoculated subcutaneously with 100 microliters (10 6 cells) of HT-29 cells using a 28 gauge insulin needle/syringe.
  • mice were euthanized by CO 2 followed by cervical dislocation either when a tumor reached >2cm in diameter or upon tumor ulceration.
  • Data Analysis Statistical analysis of tumor and blood data was performed using GraphPad Prism scientific software. Bonferonni's T test was used to compare tumor sizes between multiple groups. The Logrank test was used to determine statistical differences between group survival curves. In some cases, in which only two groups were compared,
  • mice mean tumor volumes of 5-FU/Leucovorin/Avastin treated mice were only significantly smaller than tumor volumes in 5-FU treated mice but not other treatment groups.
  • Mouse survival curves were also calculated for all treatment groups. Mice were euthanized upon overt systemic toxicity, tumor ulceration, or when tumor diameter reached >2cm. Prior to study completion (38 days from treatment initiation), ⁇ 50% of mice treated with saline, 5-FU, or 5-FU plus Avastin were still alive (Figure 9). In contrast, 92% of mice treated with 5-FU plus Avastin in combination with either 5,10- CH -THFA or leucovorin were still alive. This pattern of survival for the various drug combinations is similar to the results observed in the first nude mouse colorectal tumor study described above.
  • Example 3 Blood Analysis of Balb/c Mice Treated with combinations of 5-FU, Leucovorin, and 5,10-CH 2 -THFA
  • mice Balb/c mice were obtained from Charles River Laboratories. Mice were 6-8 weeks old at the start of all studies. Mice were maintained in isolated, hepa-filter ventilated cages with 4 mice per cage at LAB International's vivarium (San Diego, CA).
  • 5-Fluorouracil was obtained from Calbiochem.
  • Leucovorin folinic acid
  • 5 methylenetetrahydofolate was manufactured by Eprova AG.
  • Balb/c Blood Analysis Study Balb/c mice, 7 weeks old female mice, were injected for seven consecutive days with combinations of 5-FU, leucovorin, and 5,10-CH 2 -THFA. All drugs were intraperitoneally injected (100 microliters/mouse, 0.6mg/mouse/drug) using a 28 gauge insulin needle/syringe. 200-250 microliters blood/mouse was collected by retro-orbital puncture into EDTA-coated microtainer tubes (VWR International) on days 0 (prior to drug injection), 8, and 13. Complete blood counts plus blood differentials were determined by Labcorp Corporation of America using a Bayer Advia 120 Hematology analyzer.
  • 5-FU is cytotoxic towards normal cells, especially cells of the hematopoietic system due to its myelosuppressive effects.
  • leucovorin and 5,10-CH 2 - THFA we wanted to determine if there were similar toxicity profiles of 5-FU/5,10-CH 2 - THFA combination therapy.
  • mice we injected normal Balb/c mice with various combinations of 5-FU, leucovorin, and 5,10-CH 2 -THFA (Table 5).
  • Pretreatment, one week, and two weeks following treatment we analyzed complete blood counts plus differentials for changes in blood parameters.
  • we analyzed qualitative and quantitative measures of drug toxicity are examples of drugs that were treated with 5-FU/5,10-CH 2 -THFA.
  • mice After one week of drug dosing, we observed all mice had drug-related toxicity including ruffled fur, moribundity, and dehydration. Within 12 days of initiation of drug treatment, all mice in the 5-FU only and 5-FU/leucovorin treatment groups had died. In contrast, 38% of mice (5 of 13) in the 5-FU/5,10-CH 2 -THFA treatment group were alive after 14 days. Kaplan-Meier survival curves were plotted for all treatment groups ( Figure 10). Logrank statistical comparison of the 5-FU/5,10-CH 2 -THFA treatment group versus the 5-FU/Leucovorin treatment group indicated a significant difference in survival (p ⁇ 0.05). Blood analysis also revealed differences in select blood cell types ( Figure 11).
  • WBC white blood cells
  • RBC red blood cells
  • HGB hemoglobin
  • HCT hematocrit
  • MCV mean cell volume
  • MH mean cell hemoglobin
  • MCHC mean cell hemoglobin content
  • neutrophils lymphocytes
  • PPT platelets
  • eosinophils basophils
  • monocytes monocytes.
  • FU/5,10-CH 2 -THFA treatment we assessed these cell types further. Using NCI grading criteria for toxicity, we calculated the percentage of mice with either combined grade 1/2 toxicity, grade 3 toxicity, or grade 4 toxicity. For platelets, we observed 25%> of mice treated 5-FU alone developed grade 4 toxicity ( Figure 12). In contrast, no grade 4 toxicity was noted for either 5-FU/leucovorin or 5-FU/5,10-CH 2 -THFA treated mice. However, unlike 5-FU/leucovorin mice with grade 3 toxicity (45%), only 15%> of 5- FU/5,10-CH 2 -THFA treated mice developed grade 3 platelet toxicity.
  • mice with grade 4 toxicity revealed quantifiable neutrophil differences.
  • mice with grade 4 toxicity into subgroups based on their neutrophil cell count ranges following treatment ( Figure 14). This analysis revealed that 100%) of mice freated with 5-FU only, and 80% of 5-FU/leucovorin treated mice, had embarkrophil cell counts between 0 and 99. In contrast, only 40% of 5-FU/5,10-CH 2 -THFA treated mice developed this lowest level neutrophil cell count.
  • mice Balb/c mice were obtained from Charles River Laboratories. Mice were 6-8 weeks old at the start of the study. Mice were maintained in isolated, hepa-filter ventilated cages with 4 mice per cage at LAB International's vivarium (San Diego, CA). Drugs 5-Fluorouracil (5-FU) and leucovorin (leucovorin) were obtained from Sigma- Aldrich. 5, 10 methylenetetrahydofolate (5,10-CH 2 -THFA) was manufactured by Eprova AG. Gemcitabine was manufactured by Eli Lilly and purchased from Myoderm Inc..
  • Balb/c Weight Analysis Study Balb/c female mice were injected with combinations of 5-FU, leucovorin, 5,10- CH 2 -THFA, and gemcitabine.
  • 5-FU, leucovorin, and 5,10-CH 2 -THFA were intraperitoneally injected (100 microliters/mouse, 0.6mg/mouse/drug) for five consecutive days (days 1-5).
  • Gemcitabine was intraperitoneally injected (100 microliters/mouse, 100 micrograms/mouse) every three days (days 1, 4, and 7). All drugs were injected using a 27 gauge insulin needle/syringe. Mouse weights were measured using an analytical balance prior to initiation of drug dosing (prefreatment) and on day 8.
  • gemcitabine the current standard therapy for pancreatic cancer, has its own associated toxicity profile. While combination 5-FU/gemcitabine and 5- FU/leucovorin/gemcitabine therapy have been examined in the clinic and shown to have enhanced clinical activity, these combinations typically display more severe toxicity than gemcitabine alone or 5-FU/leucovorin alone. Because of the related chemical characteristics and modes of action of leucovorin and 5,10-CH 2 -THFA, we wanted to investigate the toxicity profiles of 5-FU/5,10-CH 2 -THFA in combination with gemcitabine, since 5-FU/5,10-CH 2 -THFA/gemcitabine combination therapy is a potential treatment regimen for pancreatic cancer.
  • mice Prior to initiation of drug administration (pre-treatment), randomized groups of mice (12 per group) displayed similar mean body weights. Following treatment (day 8), mouse weights decreased in all treatment groups. Using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events, the severity of weight loss was plotted for each treatment group ( Figure 15). Toxicity grading is based on the percentage weight loss from the starting baseline weight (Table 7). These results show 5-FU/5,10-CH 2 -THFA induced significantly less (p ⁇ 0.05, Fisher's exact test) grade 2-3 toxicity (50%)) than either 5-FU alone or combination 5-FU/leucovorin freatment (100%> grade 2-3 toxicity for both treatment groups).
  • 5-FU/leucovorin and 5-FU/5,10-CH 2 -THFA groups both had significantly greater percentages (p ⁇ 0.05, Logrank test) of mice survive for up to 14 days (83% for each group), compared to mice treated with only 5-FU only (36%).
  • the shortest survival time was observed in the triple drug combinations of either 5-FU/leucovorin/gemcitabine or 5- FU/5,10-CH 2 -THFA /gemcitabine in which 100% of the mice died prior to day 14.
  • 5-FU/5,10-CH 2 -THFA/gemcitabine mice did survive significantly longer (9 days, p ⁇ 0.05, Logrank test) than 5-FU/leucovorin/gemcitabine treated mice (8 days).
  • Example 5 Lymphocyte Analysis of Balb/c Mice Treated with combinations of 5- FU, leucovorin, and 5,10-CH -THFA
  • mice Balb/c mice were obtained from Charles River Laboratories. Mice were 6-8 weeks old at the start of all studies. Mice were maintained in isolated, hepa-filter ventilated cages with 4 mice per cage at LAB International's vivarium (San Diego, CA).
  • Drugs 5 -Fluorouracil (5-FU) was obtained from Calbiochem.
  • Leucovorin (leucovorin) was obtained from Sigma-Aldrich.
  • 10 methylenetetrahydofolate (5,10-CH 2 -THFA) was manufactured by Eprova AG.
  • Balb/c Blood Analysis Study Balb/c mice, 7 weeks old female mice, were injected for seven consecutive days with combinations of 5-FU, leucovorin, and 5,10-CH 2 -THFA. All drugs were intraperitoneally injected (100 microliters/mouse, 0.6mg/mouse/drug) using a 28 gauge insulin needle/syringe. 200-250 microliters blood/mouse was collected by retro-orbital puncture into EDTA-coated microtainer tubes (VWR International) on days 0 (prior to drug injection), 8, and 13. Complete blood counts plus blood differentials were determined by Labcorp Corporation of America using a Bayer Advia 120 Hematology analyzer.
  • mice in the 5-FU only and 5-FU/leucovorin treatment groups developed Grade 3-4 lymphopenia, significantly less (p ⁇ 0.05, Fisher's exact test) mice in the 5-FU/5,10-CH 2 - THFA treatment group developed this level of toxicity (62%). As such, this data suggests 5-FU/5,10-CH 2 -THFA induces milder lymphocyte toxicity than either 5-FU alone or 5-FU/leucovorin.
  • Example 6 Nude Mouse Study on HT-29 Colorectal Tumor Treatment with capecitabine (Xeloda), 5,10-methylenetetrahydrofolate (5,10-CH 2 -THFA), and leucovorin.
  • mice Nude (nu/nu) mice were obtained from Simonsen Laboratories. Mice were 6-8 weeks old at the start of all studies. Mice were maintained in isolated, hepa-filter ventilated cages with 4 mice per cage at Perry Scientific 's vivarium (San Diego, CA). Cell Lines The human colon carcinoma HT-29 was obtained from American Tissue Culture
  • ATCC American Type Culture Collection
  • HT-29 cells were prepared for injection as follows: Confluent tissue culture flasks of HT-29 cells were washed once with PBS followed by cell detachment with trypsin. Detached cells were then washed once in DMEM- 10 followed by one wash with PBS. Finally, cells were resuspended in PBS at 10 7 cells/ml. Nude mice (nu/nu) were inoculated subcutaneously with 100 microliters (10 6 cells) of HT-29 cells using a 28 gauge needle/ lml insulin syringe.
  • mice survival was followed throughout the course of the experiment ( Figure 20). These results indicated 5,10-CH 2 -THFA plus Xeloda resulted in the greatest survival (67%>) on day 33 of the experiment, with day 1 defined as the first day of drug dosing, compared to leucovorin plus Xeloda (25%) or Xeloda alone (38%). Furthermore, this data suggests mice treated with leucovorin plus Xeloda had a more rapid mortality rate as indicated by a median survival of 19 days compared to >30 days for all other treatment groups. Drug Toxicity As a surrogate marker for drug toxicity, we examined mouse body weights over time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2005/011046 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer Ceased WO2005097086A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2005231436A AU2005231436A1 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
CA002561952A CA2561952A1 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
EP05732160A EP1740182A2 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
US10/594,850 US20070280944A1 (en) 2004-04-02 2005-04-01 Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
JP2007506303A JP2007531728A (ja) 2004-04-02 2005-04-01 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用
IL178261A IL178261A0 (en) 2004-04-02 2006-09-21 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55888904P 2004-04-02 2004-04-02
US60/558,889 2004-04-02
US62547904P 2004-11-04 2004-11-04
US60/625,479 2004-11-04
US65874505P 2005-03-04 2005-03-04
US60/658,745 2005-03-04

Publications (2)

Publication Number Publication Date
WO2005097086A2 true WO2005097086A2 (en) 2005-10-20
WO2005097086A3 WO2005097086A3 (en) 2006-05-18

Family

ID=35125596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011046 Ceased WO2005097086A2 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Country Status (7)

Country Link
US (1) US20070280944A1 (enExample)
EP (1) EP1740182A2 (enExample)
JP (1) JP2007531728A (enExample)
AU (1) AU2005231436A1 (enExample)
CA (1) CA2561952A1 (enExample)
IL (1) IL178261A0 (enExample)
WO (1) WO2005097086A2 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109349A1 (en) * 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
WO2008106721A1 (en) 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20150017158A1 (en) * 2012-01-20 2015-01-15 Isofol Medical Ab Tetrahydrofolates in combination with egfr-inhibitors
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3446705A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
US10292984B2 (en) 2017-02-14 2019-05-21 Isofol Medical Ab Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition
WO2019135157A1 (en) * 2018-01-05 2019-07-11 Isofol Medical Ab Methods for treating colorectal and metastatic colorectal cancers
RU2775781C2 (ru) * 2017-02-14 2022-07-11 Исофол Медикал Аб Способы увеличения уровня 2'-дезоксиуридина (durd) в плазме и ингибирования тимидилатсинтазы

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152228A2 (en) * 2008-06-10 2009-12-17 Yale University Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen
CA2738755C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfiri treatment
CA2738753C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfox treatment
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106721A1 (en) 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
CN101657203B (zh) * 2007-03-02 2012-09-05 卧龙岗大学 抗癌药的组合物及递送方法
US8372834B2 (en) 2007-03-02 2013-02-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
WO2008109349A1 (en) * 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
US20150017158A1 (en) * 2012-01-20 2015-01-15 Isofol Medical Ab Tetrahydrofolates in combination with egfr-inhibitors
US9675617B2 (en) * 2012-01-20 2017-06-13 Isofol Medical Ab Tetrahydrofolates in combination with EGFR-inhibitors
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
IL268439B2 (en) * 2017-02-14 2024-04-01 Isofol Medical Ab Methods for increasing plasma 2'-deoxyuridine in the blood and inhibiting thymidylate synthase
IL268439B1 (en) * 2017-02-14 2023-12-01 Isofol Medical Ab Methods for increasing plasma 2'-deoxyuridine in the blood and inhibiting thymidylate synthase
US11389452B2 (en) 2017-02-14 2022-07-19 Isofol Medical Ab Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition
RU2775781C2 (ru) * 2017-02-14 2022-07-11 Исофол Медикал Аб Способы увеличения уровня 2'-дезоксиуридина (durd) в плазме и ингибирования тимидилатсинтазы
EP3848036A3 (en) * 2017-02-14 2021-08-18 Isofol Medical AB Methods for increasing blood plasma 2'-deoxyuridine (durd) and thymidylate synthase inhibition
US10639311B2 (en) 2017-02-14 2020-05-05 Isofol Medical Ab Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition
US10292984B2 (en) 2017-02-14 2019-05-21 Isofol Medical Ab Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition
US10328079B2 (en) 2017-08-24 2019-06-25 Isofol Medical Ab [6R]-MTHF multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
AU2018320069B2 (en) * 2017-08-24 2024-11-21 Isofol Medical Ab (6R)-MTHF – an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2019037899A1 (en) * 2017-08-24 2019-02-28 Isofol Medical Ab ADMINISTRATION OF MULTIPLE [6R] -MTHF BOLUSES DURING CHEMOTHERAPY BASED ON 5-FLUORO-URACILE
US11013744B2 (en) 2017-08-24 2021-05-25 Isofol Medical Ab [6R]—MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2019037898A1 (en) * 2017-08-24 2019-02-28 Isofol Medical Ab [6R] -MTHF - EFFECTIVE ALTERNATIVE TO FOLATE IN CHEMOTHERAPY BASED ON 5-FLUOROURACILE
RU2762596C2 (ru) * 2017-08-24 2021-12-21 Исофол Медикал Аб Введение множественных болюсов [6r]-mthf в химиотерапии на основе 5-фторурацила
RU2763934C2 (ru) * 2017-08-24 2022-01-11 Исофол Медикал Аб [6r]-mthf - эффективная фолатная альтернатива в химиотерапии на основе 5-фторурацила
TWI752147B (zh) * 2017-08-24 2022-01-11 瑞典商伊索弗爾醫藥公司 [6r]-亞甲基四氫葉酸-在基於5-氟尿嘧啶的化療中有效的葉酸替代物
IL272874B2 (en) * 2017-08-24 2024-04-01 Isofol Medical Ab [6R]-MTHF as an effective folate substitute in 5-fluorouracil chemotherapy
EP3446706A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446705A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf an efficient folate alternative in 5-fluorouracil based chemotherapy
IL272874B1 (en) * 2017-08-24 2023-12-01 Isofol Medical Ab [6R]-MTHF as an effective folate substitute in 5-fluorouracil chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
RU2779535C2 (ru) * 2018-01-05 2022-09-09 Исофол Медикал Аб Способы лечения колоректального и метастатического колоректального рака
WO2019135157A1 (en) * 2018-01-05 2019-07-11 Isofol Medical Ab Methods for treating colorectal and metastatic colorectal cancers
CN110573178A (zh) * 2018-01-05 2019-12-13 伊索弗尔医药公司 治疗结直肠癌和转移性结直肠癌的方法

Also Published As

Publication number Publication date
IL178261A0 (en) 2006-12-31
WO2005097086A3 (en) 2006-05-18
US20070280944A1 (en) 2007-12-06
EP1740182A2 (en) 2007-01-10
JP2007531728A (ja) 2007-11-08
AU2005231436A1 (en) 2005-10-20
CA2561952A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
Seiwert et al. The concurrent chemoradiation paradigm—general principles
Diamond et al. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy
Braun et al. New systemic frontline treatment for metastatic colorectal carcinoma
Overman et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
US20070280944A1 (en) Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
JP2015536950A (ja) Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
KR20220008316A (ko) Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법
JP2021500349A5 (enExample)
BR112019016668A2 (pt) métodos para aumentar a concentração de plasma de durd e para inibir timidilato-sintase (ts) em um indivíduo humano.
Garland et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
TWI726133B (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
JP6174044B2 (ja) Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート
Park et al. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer
Sarantopoulos et al. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
RU2482496C2 (ru) Оптимизация индивидуальных доз 5-фторурацила при режиме folfox
Carrato et al. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer
KR20070019725A (ko) 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도
A Berciano-Guerrero et al. Current trends in the chemotherapy of colorectal cancer
Azzoli et al. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial
Jeong et al. Doxifluridine versus Tegafur/Gimeracil/Oteracil (S-1) as adjuvant chemotherapy for patients with gastric cancer after gastrectomy: A propensity score-matched analysis
WO2023046305A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
Ricart et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
Ge et al. Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells
WO2019232156A1 (en) Methods of treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 178261

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005231436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007506303

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2561952

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200580012067.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005231436

Country of ref document: AU

Date of ref document: 20050401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005231436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005732160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067022939

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4035/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005732160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067022939

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10594850

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10594850

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)